Navigation Links
BioFortis and Catholic Health Initiatives' Center for Translational Research Announce Biorepository Information Technology Strategic Partnership to Drive Progress in Personalized Medicine
Date:8/24/2010

COLUMBIA, Md., Aug. 24 /PRNewswire/ -- Catholic Health Initiatives' (CHI) Institute for Research and Innovation's Center for Translational Research and BioFortis, Inc. have announced a joint strategic partnership to focus on CHI's vision in personalized healthcare initiatives for community hospitals across their system.

CHI's Center for Translational Research (CTR) is a clinical R&D and molecular diagnostics laboratory that supports the progressive advancement, commercialization, and integration of personalized medicine in CHI's community-based healthcare system. After an in-depth evaluation of existing software solutions on the market, CTR executives concluded that BioFortis' Labmatrix™ would best meet the innovative informatics needs in the areas of workflow-driven protocols, specimen biobanking, next generation diagnostics, biomarker discovery, and translational research.

With a network of more than 70 hospitals across the United States, CHI is the nation's third largest faith-based, non-profit hospital system. Leveraging this network, the CTR employs a high-quality biospecimen repository, CLIA-licensed laboratory services, and translational medicine research analysis in order to further personalized medicine. As one of the first major R&D labs serving a large community hospital network, the CTR is committed to giving healthcare professionals the latest perspectives on translational sciences for patients, who in turn shall benefit from both quality healthcare and personalized treatment plans. This combination serves as a role model for improved patient outcomes everywhere.

With the Labmatrix deployment in place, authorized physicians and scientists can easily explore and ask complex questions about collected data in a unified collaborative environment. This approach is expected to result in faster formulation and better utilization of healthcare intelligence stemming from complementary clinical and specimen-derived molecular assay data. Furthermore, Labmatrix's security framework ensures protection of highly-sensitive patient information, as well as maintaining regulatory compliance and accountability through a comprehensive audit trail infrastructure. Looking forward, BioFortis and CTR plan to create direct integrations with in-network hospitals' electronic medical records (EMR) systems, and further promote cutting-edge research advancements through secondary use of health data.

CTR National Director, Jeff Otto, PhD, MBA states, "Ensuring the continuity and security of the CTR's annotated biorepository is key to unlocking the knowledge within the samples we collect. Quality biosamples combined with Labmatrix's information technology infrastructure will allow the CTR and its partners to trust the answers that flow from our research, while protecting the privacy of our specimen donors."

About the Center for Translational Research (CTR)

Catholic Health Initiatives' CTR is an emerging participant and partner in the realization of personalized medicine. The CTR, CHI's only national laboratory, based on the campus of St. Joseph Medical Center, Towson, MD., is a venture of CHI (2009 revenue of $8.6B; 6th largest Healthcare provider in the US) who provides world class healthcare through its 72 hospitals in 18 states. The CTR will leverage its diagnostic CLIA testing, specimen procurement, biorepository, and custom development capabilities to enable improved treatment options for patients. The CTR will also act as an innovation catalyst for the CHI system focusing on personalized medicine in the healthcare setting.

About BioFortis, Inc.

BioFortis, Inc. provides software solutions for research needs of the post-genomic era within several key application areas including translational research, biobanking, biomarker discovery and clinical research. With the ability to centralize life sciences data sets in a tightly-linked, highly-annotated, and user-friendly manner, the Labmatrix application is utilized by customers as a critical component of best practices standard for research data management in the biopharmaceutical industry, academia and government research institutions.


'/>"/>
SOURCE BioFortis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
2. Back To School: Staying Healthy at School is as Easy as Learning Your ABCs
3. Healthcare Network Helps Fund Scholarships Totaling $15,000
4. Scott & White Healthcare President and CEO Alfred B. Knight, M.D. to Retire in 2011, Will Lead Foundation
5. Nanoscale DNA sequencing could spur revolution in personal health care
6. Bill Gates Named Keynote Speaker at the 2010 mHealth Summit
7. David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16
8. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
9. CBR Pharma Insights' Latest Report, The New Era of Healthcare Reform - Supporting Revenue Growth through Understanding & Adaptation
10. Medical Simulation Corporation Partners with Hutchinson Technology in Training of Healthcare Professionals on Noninvasive Tissue Oxygenation Monitoring
11. New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016 ... the "Company"), a biopharmaceutical company focused on the development and ... present at the 18 th Annual BIO CEO ... 10:00 a.m. EST in New York, NY ... CEO, will provide an update on the ongoing clinical trial ...
(Date:2/4/2016)... ... 04, 2016 , ... Franz Inc. , an early ... has been recognized As “ Best in Semantic Web Technology - USA & ... America, it’s our priority to showcase prominent professionals who are excelling in their ...
(Date:2/3/2016)... , Feb. 3, 2016  With the growing ... cliff that is underway, therapies such as monoclonal ... a whole host of indications are in high ... in the development and production of these therapeutics. ... quality and high costs, novel approaches and novel ...
(Date:2/3/2016)... ... February 03, 2016 , ... ProMIS Neurosciences ... targets (epitopes) specific to misfolded, propagating strains of Amyloid beta involved in Alzheimer’s ... therapeutics for Alzheimer’s. , Following on from the first misfolded Amyloid beta target ...
Breaking Biology Technology:
(Date:1/13/2016)... 13, 2016 ... of the  "India Biometrics Authentication & ... (2015-2020)"  report to their offering.  ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016   ... diagnostic products, today announced the closing of a $9 million ... Proceeds from the financing will be used to accelerate the ... for detecting early-stage pressure ulcers. United ... receiving CE Mark approval. The device,s introduction has been met ...
(Date:1/7/2016)... LONDON , Jan. 7, 2016 ... demand for biopharmaceutical products such as biologics and ... pressure to reduce healthcare expenditure, growing demand for ... growing aging population. Biosimilars are similar versions of ... with regards to their quality, safety, and efficacy. ...
Breaking Biology News(10 mins):